Restart of Phase 2-enabling toxicology programme

AI SummaryClose X

Sareum Holdings PLC has restarted the Phase 2-enabling toxicology programme for its selective TYK2/JAK1 inhibitor, SDC-1801, which is being developed for autoimmune diseases like psoriasis. This programme, being conducted by a global contract research organisation using existing cash resources and toxicology batch, is expected to complete its dosing phase by mid-2026 and the full Phase 2-enabling package by year-end, following preliminary pharmacokinetic work. The company is confident that this, combined with positive Phase 1 data, will support SDC-1801's advancement as a potential best-in-class, once-daily oral therapy.

Disclaimer*

UK 100

Latest directors dealings